Antagonistic Activities of Epiphytic Bacteria from Soybean Leaves against Pseudomonas syringae pv. glycinea in vitro and in planta

R. May,B. Völksch,G. Kampmann

DOI: https://doi.org/10.1007/s002489900041

IF: 4.192

1997-09-01

Microbial Ecology

Abstract:

What problem does this paper attempt to address?

Prediction of Overall Survival and Progression-Free Survival by the 18F-FDG PET/CT Radiomic Features in Patients with Primary Gastric Diffuse Large B-Cell Lymphoma.

Yi Zhou,Xue-Lei Ma,Lu-Tong Pu,Ruo-Fan Zhou,Xue-Jin Ou,Rong Tian

DOI: https://doi.org/10.1155/2019/5963607

2019-01-01

Abstract:Purpose. To determine whether the radiomic features of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) contribute to prognosis prediction in primary gastric diffuse large B-cell lymphoma (PG-DLBCL) patients. Methods. This retrospective study included 35 PG-DLBCL patients who underwent PET/CT scans at West China Hospital before curative treatment. The volume of interest (VOI) was drawn around the tumor, and radiomic analysis of the PET and CT images, within the same VOI, was conducted. The metabolic and textural features of PET and CT images were evaluated. Correlations of the extracted features with the overall survival (OS) and progression-free survival (PFS) were evaluated. Univariate and multivariate analyses were conducted to assess the prognostic value of the radiomic parameters. Results. In the univariate model, many of the textural features, including kurtosis and volume, extracted from the PET and CT datasets were significantly associated with survival (5 for OS and 7 for PFS (PET); 7 for OS and 14 for PFS (CT)). Multivariate analysis identified kurtosis (hazard ratio (HR): 28.685, 95% confidence interval (CI): 2.067–398.152, p=0.012), metabolic tumor volume (MTV) (HR: 26.152, 95% CI: 2.089–327.392, p=0.011), and gray-level nonuniformity (GLNU) (HR: 14.642, 95% CI: 2.661–80.549, p=0.002) in PET and sphericity (HR: 11.390, 95% CI: 1.360–95.371, p=0.025) and kurtosis (HR: 11.791, 95% CI: 1.583–87.808, p=0.016), gray-level nonuniformity (GLNU) (HR: 6.934, 95% CI: 1.069–44.981, p=0.042), and high gray-level zone emphasis (HGZE) (HR: 9.805, 95% CI: 1.359–70.747, p=0.024) in CT as independent prognostic factors. Conclusion. 18F-FDG PET/CT radiomic features are potentially useful for survival prediction in PG-DLBCL patients. However, studies with larger cohorts are needed to confirm the clinical prognostication of these parameters.
Construction and Validation of an 18F-Fdg-pet/ct-based Prognostic Model to Predict Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients

Xiaoqing Dong,Ruoyi Wang,Xiuhua Ying,Jiaxuan Xu,Jie Yan,Peipei Xu,Yue Peng,Bing Chen

DOI: https://doi.org/10.1080/16078454.2024.2329029

IF: 2.264

2024-01-01

Hematology

Abstract:Objective: To investigate the relationship between F-18-fluorodeoxyglucose positron emission tomography/computed tomography (F-18-FDG PET/CT) related parameters and the prognosis of multiple myeloma and to establish and validate a prediction model regarding the progression-free survival (PFS) of multiple myeloma. Methods: A retrospective analysis of 126 newly diagnosed multiple myeloma patients who attended Nanjing Drum Tower Hospital from 2014-2021. All patients underwent PET/CT before treatment and were divided into a training cohort (n = 75) and a validation cohort (n = 51). Multivariate Cox proportional hazard regression analysis incorporated PET/CT-related parameters and clinical indicators. A nomogram was established to individually predict PFS in MM patients. The model was evaluated by calculating the C-index and calibration curve. Results: Here, 4.2 was used as the cut-off value of SUVmax to divide patients into high and low groups. PFS significantly differed between patients in the high-SUVmax group and low-SUVmax group, and SUVmax was an independent predictor of PFS in newly diagnosed multiple myeloma (NDMM) patients. Univariate and multivariate cox regression analysis suggested that lactate dehydrogenase (LDH), bone marrow plasma cell (BMPC), and SUVmax affected PFS. These factors were incorporated to construct a nomogram model for predicting PFS at 1 and 2 years in NDMM patients. The C-index and calibration curves of the nomogram exhibited good accuracy and consistency, and the DCA curves suggested that the model had good clinical utility. Conclusion: The PET/CT parameter SUVmax is closely related to the prognosis of myeloma patients. The nomogram constructed in this study based on PET/CT-related parameters and clinical indicators individually predicts the PFS rate of NDMM patients and enables further risk stratification of NDMM patients.
Semi-quantitative FDG parameters predict survival in multiple myeloma patients without autologous stem cell transplantation

Hyunjong Lee,Seung Hyup Hyun,Young Seok Cho,Seung Hwan Moon,Joon Young Choi,Kihyun Kim,Kyung-Han Lee

DOI: https://doi.org/10.1186/s40644-023-00625-z

IF: 5.605

2023-10-27

Cancer Imaging

Abstract:Background: F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) is useful in multiple myeloma (MM) for initial workup and treatment response evaluation. Herein, we evaluated the prognostic value of semi-quantitative FDG parameters for predicting the overall survival (OS) of MM patients with or without autologous stem cell transplantation (ASCT). Methods: Study subjects comprised 227 MM patients who underwent baseline FDG PET/CT. Therein, 123 underwent ASCT while 104 did not. Volumes of interest (VOIs) of bones were drawn on CT images using a threshold of 150 Hounsfield units. FDG parameters of maximum standardized uptake value (SUVmax), mean SUV (SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and number of focal lesions (FLs) were measured. Kaplan-Meier survival analysis with log-rank tests and Cox proportional hazards regression analyses were performed for overall survival (OS). Results: In the ASCT cohort, R-ISS stage, MTV, and TLG were associated with survival. In the non-ASCT cohort, however, R-ISS stage was not associated with patient outcomes. In contrast, high SUVmax, SUVmean, MTV, TLG, and FL could predict worse OS (hazard ratio [HR] = 2.569, 2.649, 2.506, 2.839, and 1.988, respectively). Importantly, combining FDG parameters with R-ISS stage provided a new risk classification system that discriminated worse OS in the non-ASCT cohort significantly better than did R-ISS stage alone. Conclusions: In the non-ASCT cohort, semi-quantitative FDG parameters were significant predictors of worse OS. Furthermore, combining FDG parameters with R-ISS stage may provide a new risk staging system that can better stratify the survival of MM patients without ASCT.
Application of 18F-FDG PET/CT in staging and metabolic activity assessment of Multiple Myeloma

Lijuan Di,Jianhua Zhang,Yan Fan,Zhanli Fu,Xuchu Zhang,Guang Yu Zhao,Rong Fu Wang

2015-01-01

Abstract:1358 Objectives Staging of Multiple Myeloma(MM) is of great importance for clinical management. Durie/Salmon plus staging system which utilizes 18F-FDG PET/CT or MRI to stage MM has been introduced since 2006.Our objective is to investigate the clinical value of 18F-FDG PET/CT in staging and analyze the glucose metabolic activity of lesions of Multiple Myeloma(MM). Methods Nineteen patients with newly diagnosed MM underwent 18F-FDG PET/CT from May 2010 to Oct 2014 were enrolled in this study.The maximum standardized uptake value (SUVmax) of each patient reflecting the metabolic activity was recorded. The results of Durie/Salmon plus staging system and Durie/Salmon system were compared. The relationship between the SUVmax and the percentage of plasmacytes of bone marrow between phaseⅢ and other phases(phaseⅠandⅡ)according to Durie/Salmon plus staging and Durie/Salmon staging system were analyzed. Results Pathology types of MM were IgG(n=11)、light-chain(n=5, 4λ and1κ)、IgM(n=1) and IgA(n=2).Bone involvement patterns of MM were diffused、focal and multiple. According to Durie/Salmon plus staging system and Durie/Salmon staging system, the number of phaseⅢ、Ⅱ、Ⅰwere 11、1、7 and 5、4、10，respectively. Eight patients (42.1%, 8/19) were staged differently based on Durie/Salmon plus staging system. According to the Durie/Salmon plus staging system, the SUVmax of patients and percentage of plasmacytes of bone marrow between phaseⅢ and other phases was 6.76±2.58 vs 4.20±2.23(P=0.03)、29.19%±30.65% vs 12.50%±13.62%(P=0.19), respectively. While according to Durie/Salmon staging system, the SUVmax of patients and percentage of plasmacytes of bone marrow between phaseⅢ and other phases was 5.90±2.00 vs 5.44±3.45(P=0.72)、23.31%±33.40% vs 18.38%±12.44%(P=0.71),respectively. Conclusions According to the preliminary data, 18F-FDG PET/CT is of great clinical importance for MM staging.42.10% of patients would have been staged differently with Durie/Salmon plus staging system. The SUVmax of lesions is associated with the Durie/Salmon plus staging system.
Prognostic Value of Flowcytometric Minimal Residual Disease Combined with PET/CT at Multiple Time Points before and after Autologous Stem Cell Transplantation in Multiple Myeloma

Jingli Gu,Juan Li

DOI: https://doi.org/10.1182/blood-2021-145018

IF: 20.3

2021-11-05

Blood

Abstract:Abstract Background: Multiple myeloma is a plasma cell malignancy. With the emerging novel therapy and deepening response to therapy, minimal residual disease (MRD) now has been widely accepted as the response assessment beyond complete response. New generation flow (NGF) and new generation sequencing (NGS) assess the MRD status of the bone marrow, which might result in false-negative MRD because of the well-known spatially heterogeneous and extramedullary involvement in MM. To overcome this limitations, whole body functional imaging technique such as positron emission tomography/computed tomography (PET/CT) is required. To our knowledge, there is limited data examining the prognostic value of flow MRD and FDG-PET/CT at multiple time points before and after ASCT in MM. In this study, we aimed to elucidate the prognostic valued of MRD by flow combined with PET/CT at different time points in the long-term outcomes for transplant-eligible NDMM patients. Methods: This observational cohort study was approved by the ethnic committee of Sun Yat-sen University. The inclusion criteria were 1) patients with transplant eligible NDMM; 2) received uniform induction regimen of PAD and proceeded to the following ASCT; 3) received PET/CT scan in our hospital before receiving any anti-myeloma therapy. Whole-body 18F-FDG PET/CT was carried out in all patients at baseline and was then repeated post-induction (median 38days after the completion of induction), and at 6th, 12th and 24th month post-transplant. Flow MRD status were analyzed by 8-color multiparameter flow cytometry with the sensitivity of 10 -5. Results: From July 2012 to Apr 2017, 94 consecutive patients with transplant eligible NDMM were included in the final analysis. To standardize the PET/CT interpretation, 5-points scale of Deauville score (DS) was applied to evaluate the FDG uptake of bone marrow and focal lesions together. "Flow MRD" and "PET Deauville score" were highly discordant. No matter choosing DS 1, 2 or 3 as the cutoff for PET/CT positivity, there was no significant agreement between PET/CT and flow MRD assessment after induction. At 6th and 12th month post-transplant, neither existed the significant agreement between these 2 assessments if DS 1 or 2 as the cutoff; even if DS 3 as the cutoff, the agreement degree was very poor at these early time points post-transplant. At the 24th month post-transplant, adopting DS3 as the cutoff for PET/CT positivity, the agreement degree between flow MRD and PET/CT was significantly improved to moderate level with the kappa score of 0.579. In the univariate analysis, no matter the flow MRD status was positive or negative, patients with PET DS1-2 at each time points had similar favorable TTP (table 2) whereas patients with PET DS4-5 at each time points had similar poor TTP. In the subgroup of PET DS3, as early as after the induction, patients with flow MRD-negative already show the trend of better TTP (p = .083); while at the 6th, 12th, 24th month post-transplant, patients with flow MRD - negative had significantly better TTP than those with flow MRD - positive. In the multivariate analysis (table3), the lesion DS≤4 at baseline and standard risk FISH were Independent predictive factors for TTP and the lesion DS ≤4 was the only independent predictive factor for OS. After induction and 6th month after transplant, the baseline DS were excluded from the Cox model. The post-therapy PET DS 3 might be a good cutoff value for PET/CT MRD positivity because it significantly predicted both the TTP and OS. However, since 12th month after transplant, compared to patients with DS3, those with DS 1-2 had favorably TTP. The cutoff value shifted to DS2. Conclusion: PET/CT and flow MRD are highly discordant until 2 years after transplant for patients with NDMM. Patients with low Deauville score (1-2) had good prognosis at different time points no matter the MRD status, reflecting the importance of PET/CT in evaluation the aggressive degree of MRD clone. Patients with high Deauville score (4-5) had poor prognosis at different time points no matter the MRD status, reflecting the importance of PET/CT in overcoming the uneven and extramedullary disease in MM. The Deauville score of PET/CT remained as the independent prognosis factor at post-induction, 6 th -, 12 th -, and 24 th month post-transplant. However, the cut-off value of PET/CT Deauville score shift from score 3 before 1-year post-transplant to score 2 at and beyond 1-year post-transplant. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

hematology
18 F-FDG PET/CT in Staging and Metabolic Activity Assessment of Multiple Myeloma

Di Lijuan,Zhang Jianhua,Wang Rongfu,Fu Zhanli,Fan Yan,Zhang Xuchu,Zhao Guangyu,Cui Yonggang,Liu Meng,Kang Lei,Liao Xuhe,Wang Yanfu

DOI: https://doi.org/10.3760/cma.j.issn.2095-2848.2017.01.009

2017-01-01

Abstract:Objective To investigate the clinical value of 18 F?FDG PET/CT in staging multiple myeloma ( MM) and evaluating the glucose metabolic activity of MM. Methods A total of 25 MM patients ( 13 males, 12 females, age:39-67 years) from May 2010 to April 2015 were enrolled in this retrospective study. The SUVmax of each patient was recorded. D?S plus staging according to 18 F?FDG PET/CT was com?pared with the traditional D?S staging. The SUVmax and the percentage of plasmacytes of bone marrow of phase Ⅲ and non?phase Ⅲ ( phaseⅠand Ⅱ) according to D?S plus staging were compared. Two?sample t test and Wilcoxon rank sum test were used to analyze the data. Results In 25 MM patients, the range of SUVmax of lesions was 1.8-12?0 and the mean value was 5.15±2.74. According to D?S staging, the numbers of patients with phase Ⅰ,Ⅱ andⅢwere 7, 4 and 14, respectively. While the numbers were 3, 1 and 21 by D?S plus staging. Based on the D?S plus staging system, stages of 7 patients ( 28%, 7/25 ) were changed. According to the D?S plus staging system, the SUVmax between phaseⅢand non?phaseⅢpatients was significantly different (5.75±2.54 vs 3.00±0?70; t=2.12, P<0.05), while the percentage of plasma?cytes of bone marrow between the 2 groups had no significant difference ( 17. 50%( 4. 25%-41. 75%) vs 11?15%(10.25%-36.57%);z=0.05, P>0.05). Conclusion 18F?FDG PET/CT is of clinical importance for MM staging and metabolic activity assessment of MM.
Prognostic value of pretreatment 18F-FDG PET/CT in patients with metastatic malignant melanoma

来瑞鹤,蒋冲,滕月,孙一文,李爱梅

DOI: https://doi.org/10.3760/cma.j.cn121381-201909050-00110

2020-01-01

Abstract:Objective:To demonstrate whether 18F-FDG PET/CT metabolic parameters could predict prognosis in patients with metastatic maligant melanoma (MM). Methods:A retrospective analysis was conducted on a dataset composed of 47 patients who were newly diagnosed with metastatic MM and currently undergoing pretreatment 18F-FDG PET/CT in the Affiliated Hospital of Nanjing University Medical School, Nanjing Drum Tower Hospital from August 2011 to December 2018. Of 47 patients, 20 were male, 27 were female and median age 59 (23-86) years. All patients were treated with chemotherapy, immunotherapy or targeted therapy and follow-up time was 0.5 to 53.6 months. Melanoma-specific survival (MSS) and progression-free survival (PFS) were defined as the time from 18F-FDG PET/CT imaging to the patient's death and the patient's death or progression of the disease, separately. All patients underwent 18F-FDG PET/CT imaging before treatment.The maximum standardized uptake value (SUV max) was measured. Whole-body metabolic tumor volume (MTV) and whole-body total lesion glycolysis (TLG) were measured automatically and SUV>40% SUV max voxel boundary was used as threshold. The optimal thresholds of PET parameters were obtained using the receiver operating characteristic (ROC) curve, and the patients were divided into two groups separately according to the optimal thresholds of SUV max, whole-body MTV and whole-body TLG and six groups were obtained. The difference of MSS and PFS between the two groups were predicted by Kaplan-Meier method and Log-rank test. Univariate analysis was conducted to evaluate the prognostic value of PET parameters and clinical variables. The Cox proportional risk model multivariate analysis was used to determine whether the PET parameters can act as independent prognostic risk factors for MSS and PFS. Results:The cut-off values for SUV max, whole-body MTV, and whole-body TLG were 10.86, 8.12 cm 3, and 91.45, respectively, as shown in the ROC curve analysis. The PFS was significantly different in two groups divided by optimal thresholds of whole-body MTV or whole-body TLG, separately ( χ2=5.04, 5.02; both P<0.05). Similarly, the MSS was significantly different in two groups divided by optimal thresholds of SUV max or whole-body TLG, separately ( χ2=10.22, 4.38; both P<0.05). The univariate analysis results were as follows: the serum lactate dehydrogenase level≥245 U/L, lymphatic metastasis, SUV max>10.86 and whole-body TLG>91.45, which were associated with predictors of MSS. M l stage, whole-body MTV> 8.12 cm 3 and whole-body TLG>91.45, which were associated with PFS. The multivariate analysis results showed that SUV max>10.86, proving its potential as an independent prognostic risk factor for MSS. Conclusion:The 18F-FDG PET/CT metabolic parameter SUV max was the best predictive marker in metastatic MM patients, whole-body MTV and whole-body TLG helped for the prognosis of metastatic MM patients.
Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician’s point of view

A. Diaz

DOI: https://doi.org/10.1007/BF02699937

2003-03-01

Journal of Neuro-Oncology

Abstract:
A Novel Analytical Approach for Outcome Prediction in Newly Diagnosed NSCLC Based on [ 18 F]FDG PET/CT Metabolic Parameters, Inflammatory Markers, and Clinical Variables

Lixia Zhang,Caiyun Xu,Xiaohui Zhang,Jing Wang,Han Jiang,Jinyan Chen,Hong Zhang

DOI: https://doi.org/10.1007/s00330-022-09150-2

IF: 7.034

2022-01-01

European Radiology

Abstract:Objectives To develop a novel analytical approach based on 18 F-fluorodeoxyglucose ([ 18 F]FDG) positron emission tomography (PET) metabolic parameters, serum inflammatory markers, and clinical variables to improve the outcome prediction in NSCLC. Methods A total of 190 newly diagnosed NSCLC patients who underwent pretreatment [ 18 F]FDG PET/CT were retrospectively enrolled and divided into a training cohort ( n = 127) and a test cohort ( n = 63). Cox regression analysis was used to investigate the predictive values of PET metabolic parameters, inflammation markers, and clinical variables for progression-free survival (PFS) and overall survival (OS). Based on the results of multivariate analysis, PET-based, clinical, and combined models were constructed. The predictive performance of different models was evaluated using time-dependent ROC curve analysis, Harrell concordance index (C-index), calibration curve, and decision curve analysis. Results The combined models incorporating SULmax, MTV, NLR, and ECOG PS demonstrated significant prognostic superiority over PET-based models, clinical models, and TNM stage in terms of both PFS (C-index: 0.813 vs. 0.786 vs. 0.776 vs. 0.678, respectively) and OS (C-index: 0.856 vs. 0.792 vs. 0.781 vs. 0.674, respectively) in the training cohort. Similar results were observed in the test cohort for PFS (C-index: 0.808 vs. 0.764 vs. 0.748 vs. 0.679, respectively) and OS (C-index: 0.836 vs. 0.785 vs. 0.726 vs. 0.660, respectively) prediction. The combined model calibrated well in two cohorts. Decision curve analysis supported the clinical utility of the combined model. Conclusions We reported a novel analytical approach combining PET metabolic information with inflammatory biomarker and clinical characteristics, which could significantly improve outcome prediction in newly diagnosed NSCLC. Key Points • The nomogram incorporating SULmax, MTV, NLR, and ECOG PS outperformed the TNM stage for outcome prediction in patients with newly diagnosed NSCLC . • The established nomogram could provide refined prognostic stratification .
Prognostic Value of Metabolic Parameters Measured By 18F-FDG PET/CT In Patients With Metastatic Cutaneous Malignant Melanoma

Ruihe Lai,Chong Jiang,Zhaoqun Chu,Zhengyang Zhou,Yue Teng,Shoulin Xu,Lianjun Zhao,Zhengyun Zou,Chongyang Ding

DOI: https://doi.org/10.21203/rs.3.rs-152697/v1

2021-01-01

Abstract:Abstract Purpose: The purpose of this study was to investigate the prognostic relevance of metabolic parameters measured using 18F-FDG PET/CT in patients with metastatic cutaneous malignant melanoma (CMM).Materials and Methods: The prognostic impact of whole-body metabolic tumor volume (wMTV), whole-body tumor lesion glycolysis (wTLG), maximum standardized uptake value (SUVmax) and mean standardized uptake value (SUVmean) was evaluated in 42 metastatic CMM patients who underwent 18F-FDG PET/CT. The metabolic parameters were dichotomized by optimal cutoff values using time-dependent receiver operating characteristic (ROC) curves. In addition, univariate and multivariate analyses of the metabolic parameters were performed using the Kaplan-Meier method and Cox proportional hazards models.Results: The optimal cutoff values for disease-free survival (DFS) were 4.63 for SUVmax, 3.31 for SUVmean, 8.22 cm3 for wMTV, and 18.22 for wTLG. The optimal cutoff values for melanoma-specific survival (MSS) were 4.77 for SUVmax, 3.31 for SUVmean, 22.32 cm3 for wMTV, and 51.37 for wTLG. Thirty-two (72%) of the 42 patients experienced recurrence during the follow-up period, and 21 patients (50%) died from the disease. In univariate analysis, SUVmax greater than 4.63 (p= 0.025) and SUVmean greater than 3.31 (p= 0.011) affected DFS, while SUVmax greater than 4.77 (p= 0.039), wMTV greater than 22.32 (p= 0.023) and wMTV greater than 51.37 (p= 0.016) affected MSS. In multivariate analysis after adjustment for the effects of clinical parameters, SUVmax was the best predictive factor for DFS (p = 0.016), and SUVmax, wMTV and wTLG were the best predictive factors for MSS (p = 0.023, p = 0.018, and p = 0.007).Conclusions: SUVmax appears to be a strong independent prognostic factor for recurrence in metastatic CMM, and SUVmax, wMTV and wTLG were found to be the best predictive markers for melanoma-specific death.
Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma

Jian Cui,Zhongqing Zou,Jiayu Duan,Wenjiao Tang,Yan Li,Li Zhang,Ling Pan,Ting Niu

DOI: https://doi.org/10.3389/fimmu.2021.671904

IF: 7.3

2021-08-19

Frontiers in Immunology

Abstract:To assess patients with multiple myeloma (MM), the whole-body positron-emission tomography/computed tomography (PET/CT) occupies a pivotal position for diagnostic stratification, response evaluation, and survival prediction, while important limitations are recognized as incapable of representing tumor microenvironment. Regulatory B cells (Bregs) have been reported to have an inhibitory immune function, contributing to bone marrow (BM)-immunosuppressive microenvironment for MM. Therefore, to investigate the role of PET/CT in combination with Bregs’ ratios to predict therapeutic response and survival, we sequentially enrolled 120 patients with newly diagnosed MM (NDMM) who were treated with novel agents in our center, while conventional PET/CT parameters including maximum standard uptake value (SUVmax), ratios of BM-derived Bregs within CD19 + B cells, and patients’ clinical characteristics were collected. After a median follow-up of 28.20 months (range 7.00–46.93 months), SUVmax > 4.2 at onset, accounting for 53.2% of NDMM, was uncovered to predict inferior progression-free survival (PFS) as well as overall survival (OS). With regard to the ratios of BM-derived Bregs within CD19 + B cells, the cohort with the Bregs’ proportions lower than 10%, accounting for 46.2%, exerted poorer OS. Additionally, the patients with both SUVmax > 4.2 and Bregs’ ratios < 10%, accounting for 31.7%, yielded compromised therapeutic response and long-term survival. Collectively, this study may draw attention on the prognostic value of combination of PET/CT and Bregs’ ratios when clinical decisions are made for MM in the era of novel agents.

immunology
Prognostic prediction by 18F-FDG-PET/CT parameters in patients with neuroblastoma: a systematic review and meta-analysis

Ruimin Hu,Yan Zhang,Siying Liu,Pamela Lee,Chaohong Liu,Aiguo Liu

DOI: https://doi.org/10.3389/fonc.2023.1208531

IF: 4.7

2023-07-15

Frontiers in Oncology

Abstract:Purpose: Neuroblastoma is a solid malignant tumor with high malignancy and high risk for metastasis. The prognosis of neuroblastoma ranges from spontaneous regression to insensitivity to therapies and widespread metastasis. There is a non-invasive, panoramic imaging technique called 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography–computed tomography (PET/CT), which can provide both complete anatomical information via CT and extent of FDG uptake value in tumors via positron emission detection. PET/CT is a powerful approach to estimating tumoral metabolic activities, and PET/CT parameters have been demonstrated to be associated with the prognosis of various tumors. However, the predictive performance of PET/CT for the prognosis of neuroblastoma remains unclear. This meta-analysis aims to assess the predictive values of maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) for progression-free survival (PFS), event-free survival (EFS), and overall survival (OS) in neuroblastoma patients. Methods: Literature in PubMed, Embase, Cochrane Library, and Web of Science from January 1985 to June 2023 was searched for studies evaluating predictive values of PET/CT parameters for the prognosis of neuroblastoma. Search items mainly included "Positron Emission Tomography Computed Tomography" and "Neuroblastoma". Hazard ratio (HR) was used as a pooled statistic to assess the association of SUVmax, MTV, and TLG with PFS, EFS, and OS in neuroblastoma patients. Heterogeneity test and sensitivity analysis were performed. Results: There were eight studies included, with 325 participants. Meta-analysis showed that higher SUVmax was associated with shorter OS [HR = 1.27, 95% CI (1.11, 1.45), p = 0.001], while no association with PFS [HR = 1.03, 95% CI (0.99, 1.07), p = 0.222] and EFS [HR = 2.58, 95% CI (0.37, 18.24), p = 0.341] was presented. MTV showed no association with OS [HR = 2.46, 95% CI (0.34, 18.06), p = 0.376] and PFS [HR = 2.60, 95% CI (0.68, 9.88), p = 0.161]. There was a statistically significant association between TLG and OS [HR = 1.00, 95% CI (1.00, 1.00), p = 0.00], while the HR was 1, so the association could not be concluded, and TLG showed no association with PFS [HR = 1.00, 95% CI (0.99, 1.00), p = 0.974]. Conclusion: High SUVmax indicates poor OS in patients with neuroblastoma. The MTV and TLG are potential prognostic predictors that need to be further validated by more well-designed studies. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier 340729.

oncology
Evaluation of the Prognostic Value of the Mayo Additive Staging System and Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients

Yichuan Song,Rui Zhao,Wenxuan Fu,Jing Zhao,Qingtao Wang,Rui Zhang

DOI: https://doi.org/10.1002/cam4.70382

IF: 4.711

2024-11-06

Cancer Medicine

Abstract:Introduction This study aimed to evaluate the prognostic value of the Mayo additive staging system (MASS) and minimal residual disease (MRD) in newly diagnosed multiple myeloma (NDMM) patients. Methods A total of 238 NDMM patients were enrolled in Beijing Chaoyang Hospital. Fluorescence in‐situ hybridization and next‐generation flow cytometry were used to examine cytogenetic abnormalities and MRD, respectively. The patients were classified into three groups to compare the effects on progression‐free survival (PFS). Univariate and multivariate analyses were applied to identify the survival‐related factors. Results For MASS group, the PFS was significant difference in MASS I, II, and III patients (p = 0.0006); the patients with sustained MRD‐negative, non‐sustained MRD‐negative, sustained MRD‐positive, and non‐sustained MRD‐positive were divided into Groups 1, 2, 3, and 4, respectively. The Group 1 patients had superior PFS than Groups 2 and 3 patients (p

oncology
The Role of Pre-Treatment and Mid-Treatment 18F-FDG PET/CT Imaging in Evaluating Prognosis of Peripheral T-Cell Lymphoma-Not Otherwise Specified (PTCL-NOS)

Yafei Zhang,Guangfa Wang,Xin Zhao,Yongxian Hu,Elaine Tan Su Yin,Donghe Chen,Huatao Wang,Kui Zhao

DOI: https://doi.org/10.21203/rs.3.rs-142898/v1

2021-01-01

Abstract:Abstract Background These are limited data on pretreatment evaluation and prognosis assessments of Peripheral T-Cell Lymphoma-Not Otherwise Specified (PTCL-NOS). We aimed to determine the prognostic values of pre-treatment and mid-treatment total metabolic tumor volume (MTV), total lesion glycolysis (TLG), and Deauville 5-Point Scale (D-5PS) in accessing the prognosis of PTCL-NOS.Methods A retrospective analysis was conducted in 31 patients with pathologically diagnosed PTCL-NOS. These patients have undergone positron emission tomography-computed tomography (PET-CT) scanning before and during chemotherapy. The follow-ups were done to investigate the 2-year progression-free survival (PFS) and Overall Survival (OS) of these patients. During 18F-fluorodeoxyglucose (18F-FDG) PET/CT scans, the MTV and TLG were recorded. Meanwhile, ∆MTV and ∆TLG were calculated. On the other hand, the mid-chemotherapy assessment and staging of these 31 patients were done by utilizing D-5PS. Subsequently, based on the D-5PS scores obtained, these patients were grouped into two categories: a group of patients with a score of <4 and another group with ≥4. For these two groups of patients, the survival analysis was done by Kaplan–Meier analysis and a multivariate COX regression model. Moreover, Pearson's chi-square test (χ2 test) and Spearman rank correlation coefficient were used to comparing the collected data, respectively.Results During the two-year follow-up period, 15 out of the 31 patients experienced disease progression. The optimal threshold values for both baseline MTV and TLG were 158.16 cm 3 and 677.40.Additionally, the difference in 2-year PFS between the progressive and non-progressive groups was statistically significant (χ2=8.193, P=0.004<0.05; χ2=8.872, P=0.003<0.05), significant between-group difference was detected for MTV and for TLG (χ2=6.494, P=0.011<0.05; χ2=4.687, P=0.03<0.05). When these patients were classified into two groups according to the mid-chemotherapy Deauville score of<4 and ≥4, the statistical difference of 2-year PFS between these two groups was significant, too (χ2=14.966, P=0.001<0.05), but there is no significant between-group difference in OS (χ2=3.337, P=0.068<0.05). COX analysis revealed that D-5PS are the independent factors influencing PFS, while MTV is the independent influencing factor of OS.Conclusion In conclusion, the baseline MTV obtained by PET-CT scanning, and D-5PS are crucial prognostic factors in evaluating the prognosis of Peripheral T-Cell Lymphoma-Not Otherwise Specified (PTCL-NOS).
Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer.

Yi Li,Cheng Liu,Bibo Wang,Xichun Hu,Chengcheng Gong,Yannan Zhao,Yizhao Xie,Yingjian Zhang,Shaoli Song,Zhongyi Yang,Biyun Wang

DOI: https://doi.org/10.2147/ijgm.s293998

IF: 2.145

2021-01-01

International Journal of General Medicine

Abstract:Objective: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) can provide prognostic information, especially 18F-FDG uptake has been proven to be a predictor for the prognosis of various tumors. Nevertheless, the prognosis of other PET parameters in the metastatic setting remains unclear. This study was aimed at investigating pretreatment parameters based on 18F-FDG-PET/CT so as to estimate the progression-free survival (PFS) of metastatic breast cancer (MBC) patients receiving first-line treatment. Methods: MBC patients who underwent a whole-body 18F-FDG-PET/CT prior to first-line therapy were enrolled. The heterogeneity parameter of PET/CT was analyzed, including heterogeneity index (HI) and general parameters (metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake value (SUVmax) and mean SUV (SUVmean). PFS was used to evaluate the treatment outcome. Kaplan-Meier method was adopted to carry out survival analysis and Log rank test was conducted to make a comparison. Results: A total of 177 MBC patients were selected, in which 68 were in De novo stage IV. Thirty patients were human epidermal growth factor receptor 2 (HER2)-positive, 60 patients were triple-negative, and 87 patients were hormone receptor (HR)-positive and HER2-negative. In the whole population, patients with high baseline SUVmax, SUVmean, MTV, TLG or HI were associated with lower PFS (P=0.028, 0.005, 0.017, 0.026 and 0.035, respectively). Among the patients in De novo stage IV, those with high HI at baseline had significantly shorter PFS (P=0.001). In HR+/HER2- and HER2+ subgroups, only baseline HI showed the predictive value of PFS (P=0.023 and 0.049, respectively). In the triple-negative subgroup, high baseline SUVmax, MTV or TLG showed the predictive value of worse PFS (P=0.030, 0.011 and 0.023, respectively). Conclusion: Pretreatment 18F-FDG-PET/CT parameters show the predictive value of PFS in MBC patients receiving first-line treatment. However, predictive PET/CT parameters might be different in patients with different molecular subtypes and De novo stage IV.
[200. Short-acting anesthesias using propanidid (Epontol)].

M. Zindler

Abstract:
Predictive value of clinical characteristics and baseline 18F-FDG PET/CT quantization parameters in primary adrenal diffuse large B-cell lymphoma: a preliminary study

Wenpeng Huang,Fangfang Chao,Liming Li,Yuan Gao,Yongkang Qiu,Wei Wang,Jianbo Gao,Xingmin Han,Lei Kang

DOI: https://doi.org/10.21037/qims-23-803

2023-12-01

Abstract:Background: Primary adrenal diffuse large B-cell lymphoma (PA-DLBCL) is a rare occurrence, has a very poor prognosis, and is marked by a high risk of relapse. Accurate prediction of patient prognosis before treatment initiation, along with timely adjustment of the treatment plan, holds paramount importance. 2-Deoxy-2-[fluorine-18]-fluoro-D-glucose (18F-FDG) positron emission tomography combined with computed tomography (PET/CT) imaging techniques are conventionally performed prior to treatment initiation in DLBCL patients, offering indispensable functional and metabolic insights into lymphoma lesions. Methods: We conducted a retrospective case-control study using data collected from January 2014 to December 2022, including 24 patients diagnosed with PA-DLBCL. Clinical information of patients was collected based on inpatient medical records, including age, gender, B symptoms, adrenocorticotropic hormone (ATCH), lactate dehydrogenase (LDH), β2-microglobulin, albumin (Alb), ferritin (Fe), blood calcium, Eastern Cooperative Oncology Group performance status (ECOG-PS), International Prognostic Index, Ann Arbor staging, number of involved organs, and Hans' algorithm. Prior to treatment, all patients underwent baseline 18F-FDG PET/CT, and the metabolic parameters of the tumor were calculated using a threshold of 41% of maximum standardized uptake value (SUVmax), including metabolic tumor volume (MTV) and total lesion glycolysis (TLG). Prognostic analysis of overall survival (OS) was performed using Kaplan-Meier survival analysis, as well as univariate and multifactor Cox proportional hazards regression models. Results: The 24 enrolled patients comprised 16 men and 8 women (median age 65 years, range 51-90 years). The median follow-up period was 17.5 months (range, 1-107 months). In univariate analysis, Ann Arbor stage, β2-microglobulin, ATCH, number of involved organs, regions of lymph node involvement, treatment, chemotherapy cycles, SUVmax, MTV, and TLG showed association with OS (P<0.1). In multivariate analysis, Ann Arbor stage, β2-microglobulin, ATCH, number of involved organs, and treatment were shown to be independent prognostic factors for OS. We found that SUVmax, MTV, and TLG correlated with Ann Arbor staging (P<0.05), mean standardized uptake value (SUVmean) and TLG correlated with the number of involved organs (P<0.05). Conclusions: PA-DLBCL is characterized by a low incidence and a poor prognosis. Baseline 18F-FDG PET/CT quantization parameters showed correlations with Ann Arbor staging and number of involved organs. Increasing the sample size or prolonging the follow-up period may reveal the predictive value of PET/CT quantization parameters.
[68Ga]Pentixafor PET/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET/CT

Zhenying Chen,Apeng Yang,Aihong Chen,Jinfeng Dong,Junfang Lin,Chao Huang,Jiaying Zhang,Huimin Liu,Zhiyong Zeng,Weibing Miao

DOI: https://doi.org/10.1007/s00259-024-06621-0

Abstract:Purpose: To evaluate the prognostic performance of [68Ga]Pentixafor PET/CT at baseline for staging of patients with newly diagnosed multiple myeloma (MM) and to compare it with [18F]FDG PET/CT and the Revised-International Staging System (R-ISS). Methods: Patients who underwent [68Ga]Pentixafor and [18F]FDG PET/CT imaging were retrospectively included. Patient staging was performed according to the Durie-Salmon PLUS staging system based on [68Ga]Pentixafor PET/CT and [18F]FDG PET/CT images, and the R-ISS. Progression-free survival (PFS) at patient follow-up was estimated using the Kaplan-Meier estimator and compared using the log-rank test. Area under the receiver operating characteristic curve (AUC) was calculated to assess predictive performance. Results: Fifty-five MM patients were evaluated. Compared with [18F]FDG PET, [68Ga]Pentixafor PET detected 25 patients as the same stage, while 26 patients were upstaged and 4 patients were downstaged (P = 0.001). After considering the low-dose CT data, there was no statistically significant difference in the number of patients classified in each stage using [68Ga]Pentixafor PET/CT and [18F]FDG PET/CT (P = 0.091). [68Ga]Pentixafor PET/CT-based staging discriminated PFS outcomes in patients with different disease stages (stage I vs. stage II, stage I vs. stage III, and stage II vs. stage III; all P < 0.05), whereas for [18F]FDG PET/CT, there was only a difference in median PFS between stage I and III (P = 0.021). When staged by R-ISS, the median PFS for stage III was significantly lower than that for stage I and II (P = 0.008 and 0.035, respectively). When predicting 2-year PFS based on staging, the AUC of [68Ga]Pentixafor PET/CT was significantly higher than that of [68Ga]Pentixafor PET (0.923 vs. 0.821, P = 0.002), [18F]FDG PET (0.923 vs. 0.752 P = 0.002), and R-ISS (0.923 vs. 0.776, P = 0.005). Conclusions: [68Ga]Pentixafor PET/CT-based staging possesses substantial potential to predict disease progression in newly diagnosed MM patients.
FDG PET/CT Tumor Dissemination Characteristic Predicts the Outcome of First-Line Systemic Therapy in Non-small Cell Lung Cancer

Weiyue Tan,Yi Zhang,Jie Wang,Zhonghang Zheng,Ligang Xing,Xiaorong Sun

DOI: https://doi.org/10.1016/j.acra.2023.03.027

IF: 5.482

2023-05-18

Academic Radiology

Abstract:Rationale and Objectives To explore the correlation between the tumor dissemination characteristic at 18 F-fluoro-deoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) images and the outcome of first-line systemic therapy for stage IV non-small cell lung cancer (NSCLC). Materials and Methods The current retrospective study included 101 NSCLC patients receiving first-line systemic therapy with baseline 18 F-FDG PET/CT images available. The distance between the two lesions that were the farthest apart was defined as D max to calculate the tumor dissemination. The tumor metabolic volume (MTV) of the primary tumor and the MTV of the whole-body tumor lesions (MTV wb ) were calculated using 18 F-FDG PET/CT imaging. The Kaplan–Meier survival analyses and Cox predictive model were performed to assess the relationship between the parameters and survival. Results D max and MTV wb were independent prognostic factors for overall survival (OS) ( p = 0.019 and p = 0.011, respectively) and progression-free survival (PFS) ( p = 0.043 and p = 0.009, respectively). Poor PFS and OS were associated with high MTV wb (>54.0 cm 3 ) and high D max (>48.5 cm) ( p = 0.006 and p = 0.008, respectively). When MTV wb and D max were combined, three risk groups were stratified with no (score 0), one (score 1), or two (score 2) factors ( p < 0.001 for PFS, p < 0.001 for OS). The group with a score of 0 had a considerably longer PFS and OS than those who received a score of 1 or 2 (PFS: 61.1%, 43.5%, and 21.1%, respectively, OS: 77.8%, 54.3%, and 36.8%, respectively). Conclusion The combination of tumor dissemination characteristic (D max ) and tumor burden (MTV wb ) can further improve the prognosis stratification of NSCLC.

radiology, nuclear medicine & medical imaging

Antagonistic Activities of Epiphytic Bacteria from Soybean Leaves against Pseudomonas syringae pv. glycinea in vitro and in planta

Prediction of Overall Survival and Progression-Free Survival by the 18F-FDG PET/CT Radiomic Features in Patients with Primary Gastric Diffuse Large B-Cell Lymphoma.

Construction and Validation of an 18F-Fdg-pet/ct-based Prognostic Model to Predict Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients

Semi-quantitative FDG parameters predict survival in multiple myeloma patients without autologous stem cell transplantation

Application of 18F-FDG PET/CT in staging and metabolic activity assessment of Multiple Myeloma

Prognostic Value of Flowcytometric Minimal Residual Disease Combined with PET/CT at Multiple Time Points before and after Autologous Stem Cell Transplantation in Multiple Myeloma

18 F-FDG PET/CT in Staging and Metabolic Activity Assessment of Multiple Myeloma

Prognostic value of pretreatment 18F-FDG PET/CT in patients with metastatic malignant melanoma

Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician’s point of view

A Novel Analytical Approach for Outcome Prediction in Newly Diagnosed NSCLC Based on [ 18 F]FDG PET/CT Metabolic Parameters, Inflammatory Markers, and Clinical Variables

Prognostic Value of Metabolic Parameters Measured By 18F-FDG PET/CT In Patients With Metastatic Cutaneous Malignant Melanoma

Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma

Prognostic prediction by 18F-FDG-PET/CT parameters in patients with neuroblastoma: a systematic review and meta-analysis

Evaluation of the Prognostic Value of the Mayo Additive Staging System and Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients

The Role of Pre-Treatment and Mid-Treatment 18F-FDG PET/CT Imaging in Evaluating Prognosis of Peripheral T-Cell Lymphoma-Not Otherwise Specified (PTCL-NOS)

Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer.

[200. Short-acting anesthesias using propanidid (Epontol)].

Predictive value of clinical characteristics and baseline 18F-FDG PET/CT quantization parameters in primary adrenal diffuse large B-cell lymphoma: a preliminary study

[68Ga]Pentixafor PET/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET/CT

FDG PET/CT Tumor Dissemination Characteristic Predicts the Outcome of First-Line Systemic Therapy in Non-small Cell Lung Cancer